Abstract: The invention concerns a combination comprising transgenic factor VII and a multispecific antibody directed against factor IX and X, for simultaneous or separate administration.
Type:
Application
Filed:
June 14, 2019
Publication date:
May 19, 2022
Applicant:
Laboratoire Français du Fractionnnement et des Biotechnologies
Abstract: The invention concerns a combination comprising transgenic factor VII and a multispecific antibody directed against factor IX and X, for simultaneous or separate administration.
Type:
Application
Filed:
June 14, 2019
Publication date:
September 9, 2021
Applicant:
Laboratoire Français du Fractionnnement et des Biotechnologies